Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations
Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations
复制标题
DOI：
10.1158/1078-0432.ccr-13-0017
复制
发表时间：
2013-09-15
影响因子：
11.5
通讯作者：
Weller, Michael
中科院分区：
文献类型：
--
作者：
Hartmann, Christian;Hentschel, Bettina;Weller, Michael
目的：胶质母细胞瘤长期生存的决定因素在很大程度上仍不清楚。异柠檬酸脱氢酶（IDH）1或2突变在世界卫生组织（WHO）II级和III级胶质瘤中很常见，但在原发性胶质母细胞瘤中很少见，并且与更长的生存期相关。我们比较了69例中心确诊的胶质母细胞瘤患者的临床和分子特征，生存期>36个月（LTS-36），包括33例生存期>60个月（LTS-60）的患者，有257名患者存活
Purpose: The determinants of long-term survival in glioblastoma have remained largely obscure. Isocitrate dehydrogenase (IDH) 1 or 2 mutations are common in World Health Organization (WHO) grades II and III gliomas, but rare in primary glioblastomas, and associated with longer survival.Experimental Design: We compared clinical and molecular characteristics of 69 patients with centrally confirmed glioblastoma and survival >36 months (LTS-36), including 33 patients surviving >60 months (LTS-60), with 257 patients surviving